From 2015 to 2019, switching commercially insured patients between infliximab products yielded no patient out-of-pocket savings and resulted in no savings to insurance payers after 2019.
Mahmoud Abdel-Rasoul, MS, MPH
Advertisement
Articles by Mahmoud Abdel-Rasoul, MS, MPH
Infliximab biosimilars created price competition causing insurance claims costs for infliximab originator and infliximab biosimilars to decrease, generating significant savings to the health care system.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
2
5 Things to Know About the FDA's Peptide Reversal
3
Contributor: The Deadly Gap in the Charity Care System
4
Iberdomide Complements CAR T in Myeloma: Swarup Kimar, MD
5